Hims Hers Health is trading at $31.09, down -7.96%, amid renewed attention to the Federal Trade Commission lawsuit.
- The lawsuit alleges deceptive billing, cancellation practices, and improper sharing of sensitive health information with advertising platforms.
- The broader market backdrop is weaker, with the Nasdaq Composite down 0.66%, but regulatory action appears to be the more direct company-specific overhang.
- Market-open volume data was unavailable.